Equities

Formosa Laboratories Inc

4746:TAI

Formosa Laboratories Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)79.10
  • Today's Change0.40 / 0.51%
  • Shares traded1.09m
  • 1 Year change-20.82%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in TWD

The 2 analysts offering 12 month price targets for Formosa Laboratories Inc have a median target of 126.50, with a high estimate of 130.00 and a low estimate of 123.00. The median estimate represents a 59.92% increase from the last price of 79.10.
High64.3%130.00
Med59.9%126.50
Low55.5%123.00

Dividends

In 2023, Formosa Laboratories Inc reported a dividend of 2.00 TWD, which represents a 100.00% increase over last year. The 2 analysts covering the company expect dividends of 2.75 TWD for the upcoming fiscal year, an increase of 37.25%.
Div growth (TTM)100.00%
More ▼

Earnings history & estimates in TWD

On Nov 13, 2024, Formosa Laboratories Inc reported 3rd quarter 2024 earnings of 0.19 per share.
Average growth rate-91.95%
Formosa Laboratories Inc reported annual 2023 earnings of 1.05 per share on Mar 12, 2024.
Average growth rate-14.33%
More ▼

Revenue history & estimates in TWD

Formosa Laboratories, Inc. had 3rd quarter 2024 revenues of 1.03bn. This missed the 1.11bn consensus estimate of the 2 analysts following the company. This was 10.61% above the prior year's 3rd quarter results.
Average growth rate-1.78%
Formosa Laboratories, Inc. had revenues for the full year 2023 of 4.36bn. This was 15.80% above the prior year's results.
Average growth rate+10.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.